<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03281382</url>
  </required_header>
  <id_info>
    <org_study_id>11260</org_study_id>
    <nct_id>NCT03281382</nct_id>
  </id_info>
  <brief_title>Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic Pancreatic Cancer</brief_title>
  <official_title>PHASE 1 TRIAL OF ONCOLYTIC ADENOVIRUS-MEDIATED CYTOTOXIC AND IL-12 GENE THERAPY IN COMBINATION WITH CHEMOTHERAPY FOR THE TREATMENT OF METASTATIC PANCREATIC CANCER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henry Ford Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henry Ford Health System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase 1 trial will investigate the toxicity of combining interleukin 12 gene therapy&#xD;
      with standard chemotherapy in metastatic pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol proposes a phase 1 trial combining oncolytic adenovirus-mediated cytotoxic and&#xD;
      IL-12 gene therapy with chemotherapy in metastatic pancreatic cancer. Nine subjects (3&#xD;
      cohorts, 3 subjects/cohort) with metastatic pancreatic cancer will receive a single&#xD;
      intratumoral injection of the oncolytic Ad5-yCD/mutTKSR39rep-hIL12 adenovirus at one of three&#xD;
      dose levels (cohort 1- 1 x 1011 vp, cohort 2- 3 x 1011 vp, cohort 3- 1 x 1012 vp). Depending&#xD;
      on the location of the target lesion, the adenovirus will be injected either through the&#xD;
      stomach or duodenal wall using endoscopic ultrasound (EUS) guidance. Two days later, subjects&#xD;
      will be administered (orally) 7 days of 5-fluorocytosine (5-FC) prodrug therapy. Fourteen&#xD;
      days after completion of the 5-FC prodrug therapy course, subjects will be administered&#xD;
      chemotherapy at the discretion of the treating physician. On an optional basis, subjects will&#xD;
      be administered [18F]-FHBG, a HSV-1 TK substrate, and will undergo PET imaging to quantify&#xD;
      the intensity, persistence, and biodistribution of HSV-1 TK gene expression in the pancreas.&#xD;
&#xD;
      The primary endpoint is toxicity at day 21. A secondary endpoint is rates of ≥ grade 3 CTCAE&#xD;
      adverse events. Exploratory endpoints include 1) intensity, persistence, and biodistribution&#xD;
      of HSV-1 TK gene expression, and 2) association of immunological measurements (i.e., cytokine&#xD;
      levels, NK cytolytic activity) with toxicity and clinical outcome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity</measure>
    <time_frame>21 days</time_frame>
    <description>grade 1 - 5 CTCAE adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>&gt;= grade 3 adverse events</measure>
    <time_frame>21 days</time_frame>
    <description>grade 3 - 5 CTCAE adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PET imaging</measure>
    <time_frame>14 days</time_frame>
    <description>HSV-1 TK gene expression via [18F]-FHBG administration and PET imaging</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Metastatic Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Investigational Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a single intratumoral injection of the oncolytic Ad5-yCD/mutTKSR39rep-hIL12 adenovirus at one of three dose levels. Two days later, subjects will be administered (orally) 7 days of 5-fluorocytosine (5-FC) prodrug therapy. Fourteen days after completion of the 5-FC prodrug therapy course, subjects will be administered chemotherapy at the discretion of the treating physician. On an optional basis, subjects will be administered [18F]-FHBG, a HSV-1 TK substrate, and will undergo PET imaging to quantify the intensity, persistence, and biodistribution of HSV-1 TK gene expression in the pancreas.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad5-yCD/mutTKSR39rep-hIL12</intervention_name>
    <description>Oncolytic adenovirus expressing two suicide genes and human IL-12</description>
    <arm_group_label>Investigational Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven (biopsy or cytology) metastatic pancreatic adenocarcinoma.&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  No prior treatment (surgery, chemotherapy, radiotherapy, or biological therapy) for&#xD;
             the study cancer.&#xD;
&#xD;
          -  Zubrod performance score of 0 - 2 within 30 days of registration.&#xD;
&#xD;
          -  Subjects must have adequate baseline organ function, as assessed by the following&#xD;
             laboratory values, within 30 days before initiating the study therapy:&#xD;
&#xD;
               -  Adequate renal function with serum creatinine ≤ 1.8 mg/dL or creatinine clearance&#xD;
                  ≥ 50 mL/min/m2.&#xD;
&#xD;
               -  Absolute neutrophil count &gt; 1,000/μL.&#xD;
&#xD;
               -  Hemoglobin &gt; 8.0 g/dL.&#xD;
&#xD;
               -  Platelet count &gt; 100,000/μL.&#xD;
&#xD;
               -  Bilirubin &lt; 2.0 mg/dL.&#xD;
&#xD;
               -  SGOT and SGPT &lt; 3.0 times upper limit of normal (ULN). Subjects with liver&#xD;
                  metastases may have SGOT/SGPT &lt; 5.0 times ULN.&#xD;
&#xD;
          -  Women of childbearing potential and male participants must agree to use a medically&#xD;
             effective means of birth control throughout and for 60 days beyond the treatment phase&#xD;
             of the study.&#xD;
&#xD;
          -  Subjects on oral warfarin anticoagulation therapy may be included in this study, but&#xD;
             must have close monitoring of their coagulation parameters as altered parameters&#xD;
             and/or bleeding have been reported in patients taking Xeloda® and such agents&#xD;
             concomitantly. Subjects on other forms of anti-coagulation therapies may need close&#xD;
             clinical monitoring for signs or symptoms of bleeding.&#xD;
&#xD;
          -  The subject must possess the ability to give informed consent and express a&#xD;
             willingness to meet all of the expected requirements of the protocol for the duration&#xD;
             of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant and lactating women.&#xD;
&#xD;
          -  Clinical or laboratory evidence of pancreatitis, based on discretion of treating&#xD;
             physician.&#xD;
&#xD;
          -  Serious non-malignant disease (e.g., congestive heart failure or uncontrolled&#xD;
             infections), which, in the opinion of the investigator would compromise study&#xD;
             objectives.&#xD;
&#xD;
          -  Major surgery planned within 3 months of registration other than diagnostic procedures&#xD;
             such as laparoscopy or endoscopic ultrasound and stenting or PEG/PEJ placement.&#xD;
&#xD;
          -  Islet cell tumor, benign cyst, peri-ampullary carcinoma or any non-adenocarcinomas.&#xD;
&#xD;
          -  Acute infection. Acute infection is defined by any viral, bacterial, or fungal&#xD;
             infection that has required specific therapy within 72 hours of initiation of the&#xD;
             study therapy (defined as day 1).&#xD;
&#xD;
          -  Previous history of liver disease including hepatitis.&#xD;
&#xD;
          -  Positive serologic test for Hepatitis B or C at baseline.&#xD;
&#xD;
          -  Immunosuppressive therapy including systemic corticosteroids. Use of inhaled and&#xD;
             topical corticosteroids is permitted.&#xD;
&#xD;
          -  Impaired immunity or susceptibility to serious viral infections.&#xD;
&#xD;
          -  Allergy to any product used on the protocol.&#xD;
&#xD;
          -  Serious medical or psychiatric illness or concomitant medication, which, in the&#xD;
             judgment of the investigator, might interfere with the subject's ability to respond to&#xD;
             or tolerate the treatment or complete the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David Kwon, MD</last_name>
    <phone>3139169930</phone>
    <email>dkwon1@hfhs.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Janice Freytag, BS</last_name>
    <phone>3138748326</phone>
    <email>jfreyta1@hfhs.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Kwon, MD</last_name>
      <phone>313-916-9930</phone>
      <email>dkwon1@hfhs.org</email>
    </contact>
    <contact_backup>
      <last_name>Janice Freytag, BS</last_name>
      <phone>3138748236</phone>
      <email>jfreyta1@hfhs.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>September 11, 2017</study_first_submitted>
  <study_first_submitted_qc>September 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2017</study_first_posted>
  <last_update_submitted>September 11, 2017</last_update_submitted>
  <last_update_submitted_qc>September 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henry Ford Health System</investigator_affiliation>
    <investigator_full_name>David Kwon, MD</investigator_full_name>
    <investigator_title>Medical Director, Center for Cancer Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

